Get access

Tramadol plus metamizole combined or not with anti-inflammatory drugs is clinically effective for moderate to severe chronic pain treatment in cancer patients

Authors

  • Patrícia B Flôr,

    1. Departamento de Cirurgia, Faculdade de Medicina Veterinária e Zootecnia, Universidade de São Paulo, São Paulo, SP, Brazil
    Search for more papers by this author
  • Karina VB Yazbek,

    1. Departamento de Cirurgia, Faculdade de Medicina Veterinária e Zootecnia, Universidade de São Paulo, São Paulo, SP, Brazil
    Search for more papers by this author
  • Keila K Ida,

    Corresponding author
    1. Laboratório de Investigação Médica LIM-08, Programa de Pós-Graduação em Anestesiologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil
    • Departamento de Cirurgia, Faculdade de Medicina Veterinária e Zootecnia, Universidade de São Paulo, São Paulo, SP, Brazil
    Search for more papers by this author
  • Denise T Fantoni

    1. Laboratório de Investigação Médica LIM-08, Programa de Pós-Graduação em Anestesiologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil
    Search for more papers by this author

Correspondence: Keila Ida, Faculdade de Medicina da Universidade de São Paulo, Laboratório de Investigação Médica LIM-08, Av. Doutor Arnaldo, 455, 2º andar - sala 2120, Cerqueira César, 01246-903, São Paulo, SP, Brazil. E-mail: keilaida@usp.br

Abstract

Objective

To test the effectiveness and safety of tramadol plus metamizole combined or not with a non-steroidal anti-inflammatory drug (NSAID) for treating moderate to severe chronic neoplastic pain in dogs, and its impact on quality of life (QL).

Study design

Prospective, uncontrolled, open-label, clinical study.

Animals

Sixty nine client-owned dogs with multiple forms of cancer and visual analog scale (VAS) pain score ≥40 after receiving NSAIDs for at least 7 days.

Methods

The MN group received metamizole + NSAID, MNT group received metamizole + NSAID + tramadol and MT group received metamizole + tramadol. Pain was scored by the 0 to 100 mm VAS (0 = no pain, 100 = worst pain) and analgesic therapy was considered effective if 25 mm differences in VAS scores were observed between day 0 and the follow ups. The QL was evaluated according to a 0 to 36 scoring method for dogs (0 = worst, 36 = best) and side effects were recorded. Data were registered at day 0 (baseline) and at the first and second follow ups (7 and 14 days after day 0, respectively).

Results

The MN group had less analgesia at day 7 (25%) and day 14 (42%) than MNT (59%, = 0.0274; 76%, = 0.0251, respectively) and MT groups (69%, = 0.0151; 81%, = 0.0341, respectively). The QL scores were lower in the MN group at the first (score 23) and second follow up (score 26) than in MNT (27, = 0.0847; 30, = 0.0002) and MT (28, = 0.0384; 31, = 0.0001) groups. Side effects were more commonly observed in the MN group (87%) than in MNT (24%, < 0.0001) and MT groups (25%, = 0.0003) at the first follow up.

Conclusions and clinical relevance

Tramadol plus metamizole combined or not with NSAID were well tolerated and clinically effective to treat moderate to severe pain in dogs with cancer and improved QL.

Ancillary